Switch Rates and Total Cost of Care Associated with Apremilast and Biologic Therapies in Biologic-Naive Patients with Plaque Psoriasis

PURPOSE: Compare treatment switching rates and costs among biologic-naive psoriasis patients initiating apremilast or biologics. METHODS: This retrospective claims analysis used IBM MarketScan Commercial and Medicare Supplemental databases to identify patients who initiated apremilast or a biologic...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaplan, David L, Ung, Brian L, Pelletier, Corey, Udeze, Chuka, Khilfeh, Ibrahim, Tian, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373411/
https://www.ncbi.nlm.nih.gov/pubmed/32765022
http://dx.doi.org/10.2147/CEOR.S251775

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373411/
https://www.ncbi.nlm.nih.gov/pubmed/32765022
http://dx.doi.org/10.2147/CEOR.S251775

Ejemplares similares